In Vivo Therapeutics Core

Services

In Vivo Therapeutics core personnel are highly trained and have extensive experience in many different animal models, dose routes and species (including surgical and stereotactic procedures).

Pharmacological Investigations:

In vitro toxicity testing

  • Utilize primary human hematopoietic cells and clonogenic progenitor assays to test effects of new compounds on normal cellular function
In vivo dose range finding
  • Coordinate pharmacokinetic studies with the Clinical Pharmacology Analytical Core (CPAC) in the School of Medicine
  • Develop a rational dosing regimen for testing efficacy of therapyAssess potential in vivotoxicity of new compounds and/or combination therapies
  • Coordinate end-point analysis (necropsy and histology) with Preclinical Histology Core in the IU School of Medicine
In vivo tumor growth kinetics
  • Facilitate development of novel xenograft models
  • Document tumor progression of previously untested tumors prior to drug efficacy study in immunodeficient mice.

Tumor cell lines currently available:

  • U87-MG (Glioblastoma),
  • GBM primary patient xenografts
  • SKOV-3X & A2780 (Ovarian) 
  • A549, H460, H1975 (Lung) 
  • MCF-7, TMD-231, MDA-MB-468, BT474 (Breast)
  • C32 (Melanoma)
  • H929 & MM1S (Multiple Myeloma)
  • Raji & Granta-519 (NHL)
  • PaCa-2, ASPC-1, Panc-1 (Pancreatic)
  • IMR32 (Neuroblastoma)
  • CHLA-9, CHLA-10, TC-71 (Ewing Sarcoma)
In vivo drug efficacy/tumor xenograft model
  • Establish tumors and administer drug regimen
  • Document tumor progression in vehicle- and drug-treated mice
  • Coordinate longitudinal imaging with the In vivo imaging core 
  • Coordinate end-point analysis (necropsy and histology) with Preclinical Histology Core in the IU School of Medicine
Cellular Therapies:
  • Radiation of mice prior to transplantation
  • Intravenous injection of hematopoietic stem cells into mice
  • Provide investigator blood samples from transplanted mice